Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 25, 2023, to announce its financial results for the fiscal quarter ended September 30, 2023. The press release containing these results, furnished as Exhibit 99.1, is the primary focus of this filing, providing investors with key performance indicators and financial condition details for the period. Investors should review the furnished press release for specific figures related to revenue, earnings, and any forward-looking statements or guidance provided by the company. This filing serves as the official communication channel for TMO's third-quarter performance. While the 8-K itself is brief, it directs stakeholders to the comprehensive press release for the substantive financial information. This includes insights into the company's operational performance, segment results, and overall financial health, which are crucial for assessing the company's trajectory and investment potential.
Key Highlights
- 1Announcement of Q3 2023 financial results on October 25, 2023.
- 2The press release containing detailed financial results is furnished as Exhibit 99.1.
- 3The filing is made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- 4Information provided is not deemed 'filed' for certain sections of the Securities Exchange Act of 1934, but incorporated by reference in other filings as specified.
- 5Investors are directed to the press release for specific financial data and commentary.
- 6This 8-K serves as the official notification of the company's quarterly performance.